Physician profile
Aliyeah Roper
NPI 1386955532
$1,158.45
in general payments reported to CMS, 2019-2025
15 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.76 · 2020: $43.41 · 2021: $41.29 · 2022: $17.35 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $198.87 | 2025 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $155.71 | 2025 | Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.55 | 2025 | Relistor |
| Janssen Pharmaceuticals, INC | $130.00 | 2019-2022 | |
| Boston Scientific Corporation | $106.39 | 2025 | Intracept |
| Globus Medical, INC. | $105.58 | 2025 | Senza |
| Averitas Pharma INC. | $64.23 | 2025 | Qutenza |
| Abbott Laboratories | $52.81 | 2020-2021 | |
| Abbvie INC. | $48.35 | 2025 | |
| Nalu Medical, INC. | $46.38 | 2025 | Nalu Neurostimulation System |
| Valinor Pharma, LLC | $35.01 | 2025 | Movantik |
| Spr Therapeutics, INC | $28.27 | 2025 | Sprint Pns System |
| Stryker Corporation | $18.64 | 2025 | Mild Device Kit |
| Vertex Pharmaceuticals Incorporated | $17.58 | 2025 | |
| Bioventus LLC | $16.08 | 2025 | Gelsyn-3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliyeah Roper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.